Novartis introduces Lucentis® in state of the art pre-filled syringe
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
List view / Grid view
News
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
AstraZeneca proposes appointment of Ann Cairns as Non-Executive Director
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
Pfizer’s investigational vaccine candidate bivalent rLP2086 receives U.S. Food and Drug Administration breakthrough therapy designation for potential prevention of meningococcal B disease
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
EMA publishes its work programme for 2014
19 March 2014 | By The European Medicines Agency
The European Medicines Agency has published its work programme for 2014...
Sanofi Pasteur allies with SK Chemical Co. of South Korea on pneumococcal conjugate vaccine
19 March 2014 | By Sanofi
A long-term strategic business collaboration to co-develop and commercialize an innovative vaccine against pneumococcal infection to address global public-health needs...
Pfizer launches 2013 integrated annual review
19 March 2014 | By Pfizer Inc
Pfizer Inc. announced the launch of its fourth integrated annual review, which summarizes the company’s 2013 financial, environmental and social responsibility performance...
Astellas Pharma and Daiichi Sankyo form compound library sharing partnership
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™
18 March 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY...
First patients enrolled into European Phase III programme for potential first in class oral treatment for anaemia associated with chronic kidney disease
18 March 2014 | By Astellas
Roxadustat could change treatment of anaemia associated with CKD and remove the need for multiple injections...
Lundbeck and Otsuka initiate European launch of Abilify Maintena®, a once-monthly formulation for the treatment of schizophrenia
18 March 2014 | By Lundbeck
Denmark is the first country in Europe where Abilify Maintena® is fully reimbursed and accessible to people diagnosed with schizophrenia...
Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement to discover novel immuno-oncology therapies
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...
Amgen announces positive top-line results from Phase 3 TESLA trial of evolocumab in patients with homozygous familial hypercholesterolemia
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS®
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies...
